BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 29567362)

  • 1. BRAF V600E mutation in papillary thyroid cancer and its effect on postoperative radioiodine (
    Domínguez Ayala M; Expósito Rodríguez A; Bilbao González A; Mínguez Gabiña P; Gutiérrez Rodríguez T; Rodeño Ortiz de Zarate E; García Carrillo M; Barrios Treviño B
    Cir Esp (Engl Ed); 2018 May; 96(5):276-282. PubMed ID: 29567362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of BRAF V600E mutation in post-surgical 131I therapy in papillary thyroid carcinoma: a study based on SPECT-CT uptake analysis.
    Domínguez-Ayala M; Mínguez-Gabiña P; Paja-Fano M; Bilbao-González A; Expósito-Rodríguez A; Rodeño-Ortiz de Zarate E
    Q J Nucl Med Mol Imaging; 2023 Mar; 67(1):83-92. PubMed ID: 34477344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
    Li J; Liang J; Zhao T; Lin Y
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Genetic Duet of
    Liu J; Liu R; Shen X; Zhu G; Li B; Xing M
    J Nucl Med; 2020 Feb; 61(2):177-182. PubMed ID: 31375570
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunohistochemical detection of the BRAF V600E mutation in papillary thyroid carcinoma. Evaluation against real-time polymerase chain reaction.
    Paja Fano M; Ugalde Olano A; Fuertes Thomas E; Oleaga Alday A
    Endocrinol Diabetes Nutr; 2017 Feb; 64(2):75-81. PubMed ID: 28440781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF V600E and Retinoic Acid in Radioiodine-Refractory Papillary Thyroid Cancer.
    Groener JB; Gelen D; Mogler C; Herpel E; Toth C; Kender Z; Peichl M; Haufe S; Haberkorn U; Sulaj A; Zemva J; Kopf S; Nawroth PP; Brune M; Rudofsky G
    Horm Metab Res; 2019 Jan; 51(1):69-75. PubMed ID: 30396219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
    Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
    World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.
    Rothenberg SM; McFadden DG; Palmer EL; Daniels GH; Wirth LJ
    Clin Cancer Res; 2015 Mar; 21(5):1028-35. PubMed ID: 25549723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.
    Elisei R; Viola D; Torregrossa L; Giannini R; Romei C; Ugolini C; Molinaro E; Agate L; Biagini A; Lupi C; Valerio L; Materazzi G; Miccoli P; Piaggi P; Pinchera A; Vitti P; Basolo F
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4390-8. PubMed ID: 23066120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcome of Radioiodine Therapy in Low-intermediate Risk Papillary Thyroid Carcinoma with BRAF(V600E) Mutation.
    Li J; Yang T; Zhao T; Liang J; Lin YS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Jun; 38(3):346-50. PubMed ID: 27544995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
    Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
    Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
    Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.
    Gao WL; Wie LL; Chao YG; Wie L; Song TL
    Clin Lab; 2012; 58(9-10):919-26. PubMed ID: 23163107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of BRAF V600E mutation detection of fine-needle aspiration biopsy on diagnosis and treatment guidance of papillary thyroid carcinoma.
    Qi W; Shi C; Zhang P; Feng L; Wang J; Chen D
    Pathol Res Pract; 2020 Aug; 216(8):153037. PubMed ID: 32703500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increase in Papillary Thyroid Cancer Incidence Is Accompanied by Changes in the Frequency of the BRAF V600E Mutation: A Single-Institution Study.
    Kowalska A; Walczyk A; Kowalik A; Pałyga I; Trybek T; Kopczyński J; Kajor M; Chrapek M; Pięciak L; Chłopek M; Góźdź S; Kamiński G
    Thyroid; 2016 Apr; 26(4):543-51. PubMed ID: 26889698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive Value of BRAF
    Song JY; Sun SR; Dong F; Huang T; Wu B; Zhou J
    Curr Med Sci; 2018 Oct; 38(5):785-797. PubMed ID: 30341513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to therapy of papillary thyroid cancer of known BRAF status.
    Kowalska A; Walczyk A; Kowalik A; Pałyga I; Gąsior-Perczak D; Trybek T; Kopczyński J; Kajor M; Mikina E; Szymonek M; Gadawska-Juszczyk K; Szyska-Skrobot D; Lizis-Kolus K; Hurej S; Chrapek M; Chłopek M; Góźdź S
    Clin Endocrinol (Oxf); 2017 Dec; 87(6):815-824. PubMed ID: 28718951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined BRAF
    Campennì A; Ruggeri RM; Siracusa M; Pignata SA; Di Mauro F; Vento A; Trimarchi F; Baldari S
    J Endocrinol Invest; 2018 Nov; 41(11):1283-1288. PubMed ID: 29549631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF
    Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
    World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
    Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
    Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.